Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole For Use As A Medicament

Patent No. EP3977993 (titled "Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole For Use As A Medicament") was filed by Pfizer on Aug 31, 2015. The application was issued on Jan 31, 2024.

Patent Summary

This invention provides a crystalline form (Form 1) of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament, specifically to stabilize transthyretin (TTR) and inhibit TTR amyloid fibril formation in treating transthyretin amyloid diseases. Form 1 is characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 2θ of 15.4 ± 0.2, 20.2 ± 0.2, 28.6 ± 0.2, and 29.0 ± 0.2, and a solid-state NMR spectrum with $^{13}$C chemical shifts at 120.8 ± 0.2 and 127.7 ± 0.2 ppm. The form may be substantially pure, consist of needles, or exist in mixtures with other polymorphs (e.g., Forms 2, 4, 6). Form 1 is utilized to ensure pharmaceutical stability, purity, and consistent dissolution rates in dosage forms.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
KELTIEOct 31, 2024KELTIE
QUIMICA SINTETICAOct 29, 2024AERA
QUIMICA SINTETICAOct 29, 2024BARDEHLE PAGENBERG SL

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3977993

PFIZER
Application Number
EP21203965A
Filing Date
Aug 31, 2015
Status
Granted And Under Opposition
Dec 29, 2023
Publication Date
Jan 31, 2024